Enrofloxacin in Avian Medicine: Pharmacokinetics, Indications, and Regulatory Considerations

Introduction

Enrofloxacin is a synthetic fluoroquinolone antimicrobial agent developed exclusively for veterinary use. It exerts bactericidal activity through inhibition of bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby disrupting DNA replication, transcription, and repair in susceptible gram-negative and gram-positive bacteria [1]. In avian medicine, enrofloxacin is employed extensively for the treatment of systemic bacterial infections, particularly those caused by Enterobacteriaceae and Pasteurellaceae [2, 1]. Its favorable pharmacokinetic profile, characterized by high oral bioavailability, extensive tissue distribution, and a long elimination half-life in many bird species, underpins its clinical utility [3, 1]. However, concerns regarding antimicrobial resistance, tissue residues, and ecotoxicological impacts have prompted increasingly stringent regulatory oversight [4, 5, 6, 7]. This article provides a comprehensive, publication-grade review of [avian enrofloxacin] with emphasis on pharmacokinetics, therapeutic indications, pharmacodynamic relationships, residue depletion, and regulatory considerations.

Pharmacokinetics of Enrofloxacin in Avian Species

Enrofloxacin is administered via the oral (drinking water or feed), intramuscular, or subcutaneous route in poultry and companion birds [1]. Following absorption, enrofloxacin undergoes partial hepatic de-ethylation to its primary active metabolite, ciprofloxacin, which also possesses potent antimicrobial activity [3, 1]. The pharmacokinetic parameters of enrofloxacin vary considerably among avian species, breeds, and age classes. A comprehensive study in five chicken breeds demonstrated significant breed-related differences in the rate of drug clearance and volume of distribution, necessitating breed-specific dose optimization [4].

In broiler chickens, Monte Carlo simulations based on population pharmacokinetic data have established optimal dosage regimens for the treatment of colibacillosis. Felix et al. demonstrated that a dose of 10 mg/kg administered orally once daily achieves the pharmacodynamic target of an area under the concentration-time curve over 24 hours to minimum inhibitory concentration (AUC24/MIC) ratio of greater than 125 for susceptible Escherichia coli isolates [2]. Similarly, pharmacokinetic/pharmacodynamic (PK/PD) modeling against Klebsiella pneumoniae in young chicks revealed that an AUC24/MIC ratio of 100 to 125 predicts clinical and microbiological cure [8].

Ocular penetration of enrofloxacin is a critical consideration for treating intraocular infections. Fuchs et al. quantified enrofloxacin concentrations in the aqueous humour of avian eyes following systemic administration and found that therapeutic levels exceeded the MIC90 for common avian ocular pathogens, supporting its use in conditions such as infectious keratitis and uveitis [3].

Drug-drug interactions significantly influence enrofloxacin pharmacokinetics. Co-administration with cyclosporine A, a P-glycoprotein inhibitor, increased the systemic exposure of enrofloxacin in chickens, while activated charcoal markedly reduced its absorption [9]. Additionally, the flavonoid morin has been shown to enhance enrofloxacin bioavailability through inhibition of ATP-binding cassette (ABC) transporters while concurrently providing hepatoprotective effects via antioxidant pathway activation [10]. These findings highlight the potential for rationally designed adjunctive therapies to improve therapeutic outcomes.

Pharmacodynamics and Antimicrobial Activity

Enrofloxacin exhibits concentration-dependent killing, with the ratio of peak serum concentration to MIC (Cmax/MIC) and AUC24/MIC serving as the primary predictors of efficacy [2, 8]. The drug displays broad-spectrum activity against avian pathogenic Escherichia coli (APEC), Pasteurella multocida, Salmonella spp., Mycoplasma gallisepticum, and Klebsiella pneumoniae [2, 8, 1]. However, the emergence of fluoroquinolone resistance, mediated primarily by mutations in the quinolone resistance-determining regions (QRDRs) of gyrA and parC, as well as plasmid-mediated quinolone resistance (qnr) genes, has been documented in poultry isolates globally [2, 7].

Subtherapeutic exposure is a well recognized driver of resistance selection. The dose-dependent impact of enrofloxacin on the broiler chicken gut resistome has been characterized by metagenomic analysis. Temmerman et al. reported that enrofloxacin administration at therapeutic doses transiently enriched the relative abundance of fluoroquinolone resistance genes in the cecal microbiome, while subtherapeutic dosing caused a more pronounced and sustained expansion of the resistome [7]. Importantly, co-administration of a synbiotic formulation mitigated these resistome alterations, suggesting a potential non-antimicrobial intervention to preserve gut microbial diversity during therapy [7].

Indications for Use in Avian Species

Enrofloxacin is indicated for the treatment of systemic and localized bacterial infections in poultry, waterfowl, and companion birds. Primary indications include:

• Colibacillosis: Enrofloxacin is a first-line therapy for avian pathogenic Escherichia coli infections, including airsacculitis, pericarditis, perihepatitis, salpingitis, and omphalitis [2, 1]. PK/PD-optimized dosing regimens have been established for this indication [2].
• Fowl Cholera: Caused by Pasteurella multocida, this septicemic disease responds well to enrofloxacin therapy [1].
• Salmonellosis: Enrofloxacin is used to treat Salmonella Pullorum and Salmonella Gallinarum infections, though regulatory restrictions on off-label use in layers and breeders exist in many jurisdictions [1].
• Mycoplasmosis: Enrofloxacin demonstrates activity against Mycoplasma gallisepticum and Mycoplasma synoviae [1].
• Secondary bacterial infections: In viral respiratory disease complexes, enrofloxacin is frequently employed to control secondary bacterial pathogens. Abbasnia et al. investigated the effect of enrofloxacin on clinical parameters and the mucociliary system of broilers co-infected with H9N2 avian influenza virus and infectious bronchitis virus. Their results indicated that enrofloxacin reduced clinical severity but did not entirely restore mucociliary clearance function [11].

Impact on Viral-Bacterial Co-Infections

Viral respiratory infections in poultry are frequently complicated by secondary bacterial invasion, which exacerbates clinical disease and increases mortality. The use of enrofloxacin in such contexts must be carefully weighed against the risk of selecting for antimicrobial resistance. In a controlled challenge model, enrofloxacin administration to broilers co-infected with H9N2 low pathogenicity avian influenza virus and infectious bronchitis virus led to improved clinical scores and reduced bacterial load, yet the drug did not reverse virus-induced ciliary damage [11]. This finding underscores the importance of concurrent supportive care and biosecurity measures when using antimicrobials in viral respiratory outbreaks.

Residue Depletion and Withdrawal Periods

Regulatory frameworks governing enrofloxacin use in food-producing birds are predicated on establishing safe withdrawal periods that ensure tissue residues fall below maximum residue limits (MRLs) at slaughter [4, 5, 6]. The depletion kinetics of enrofloxacin and its metabolite ciprofloxacin have been extensively characterized in edible tissues (muscle, liver, kidney, skin/fat) and in non-edible matrices such as feathers [5, 6].

Chen et al. conducted a comprehensive residue depletion study across five chicken breeds and reported significant interbreed variability in the rate of drug clearance from muscle and liver tissues [4]. Such breed-specific differences have direct implications for the establishment of universal withdrawal periods and suggest that breed-specific recommendations may be necessary to ensure consumer safety.

Feathers have emerged as a persistent reservoir for fluoroquinolone residues. Using quantitative UHPLC-MS/MS, Ringenier et al. demonstrated that enrofloxacin and flumequine residues remain detectable in feathers of broilers and parent stock for extended periods, often exceeding the withdrawal times established for edible tissues [5, 6]. The persistence of residues in feathers raises questions about the potential for feather meal contamination and environmental dissemination of antimicrobial residues through litter and compost [5, 6].

Regulatory Considerations and Antimicrobial Stewardship

Regulatory oversight of enrofloxacin use in poultry varies internationally but generally incorporates restrictions on extra-label use, prohibition of use in laying hens producing eggs for human consumption, and mandatory adherence to withdrawal periods [1]. The World Organisation for Animal Health (WOAH) classifies fluoroquinolones as veterinary critically important antimicrobials, and many national authorities require veterinary prescription and limit prophylactic or metaphylactic use [1].

The emergence of fluoroquinolone-resistant zoonotic pathogens, particularly Campylobacter and Salmonella, has led to heightened scrutiny of enrofloxacin use in food animals [7, 1]. In some regions, the approval for use in poultry has been withdrawn entirely, while others have imposed mandatory susceptibility testing prior to prescription [1]. Antimicrobial stewardship principles advocate for the targeted, short-term use of enrofloxacin only when culture and sensitivity results confirm susceptibility and when no narrower-spectrum alternative is available.

Deng et al. proposed a novel stewardship strategy involving the co-administration of morin to enhance enrofloxacin efficacy while reducing the required dose and duration [10]. By inhibiting ABC transporters, morin increases intestinal absorption and reduces biliary excretion of enrofloxacin, thereby achieving therapeutic plasma concentrations with lower administered doses. Simultaneously, morin's antioxidant properties mitigate enrofloxacin-induced hepatotoxicity, improving the safety profile of therapy [10].

Adverse Effects and Toxicity

Enrofloxacin is generally well tolerated in birds at recommended doses. However, high doses or prolonged therapy have been associated with arthropathy in young, rapidly growing birds, a class effect of fluoroquinolones attributable to chelation of magnesium ions in articular cartilage [1]. Gastrointestinal disturbances, including diarrhea and dysbiosis, may occur secondary to disruption of the intestinal microbiota. The impact on the gut resistome, as described by Temmerman et al., highlights the need for judicious use to minimize collateral damage to the commensal microbiome [7].

Diagnostic Approaches for Monitoring Therapy

Therapeutic drug monitoring (TDM) is not routinely performed in avian practice but may be indicated in cases of treatment failure or suspected toxicity. High-performance liquid chromatography (HPLC) and UHPLC-MS/MS are the reference methods for quantifying enrofloxacin and ciprofloxacin concentrations in plasma and tissues [5, 6]. Microbiological assays, including agar diffusion, can provide semiquantitative estimates of antimicrobial activity but lack the specificity to distinguish parent drug from active metabolite [1].

The decision tree below outlines a clinical algorithm for initiating and monitoring enrofloxacin therapy in avian patients.

flowchart TD
    A[Clinical suspicion of bacterial infection], > B{Obtain samples for C&S}
    B, > C[Empiric enrofloxacin initiated\nbased on local epidemiology]
    C, > D[Confirm pathogen identification\nand MIC determination]
    D, > E{Isolate susceptible to enrofloxacin?}
    E, > |Yes| F[Continue therapy for 3-5 days\nMonitor clinical response]
    E, > |No| G[Switch to alternative antimicrobial\nbased on C&S results]
    F, > H[Re-evaluate at 48-72 hours]
    H, > I{Clinical improvement?}
    I, > |Yes| J[Complete course and\nadhere to withdrawal period]
    I, > |No| K[Re-culture, consider TDM,\nand rule out co-infections]
    K, > L[Adjust therapy as indicated]

Future Perspectives and Research Needs

The optimal use of enrofloxacin in avian medicine requires continued refinement of dosing regimens through population PK/PD modeling, particularly for emerging pathogens and resistant strains [2, 8]. Further research is needed to characterize the environmental fate of enrofloxacin residues in poultry litter and the potential for selection of resistance in soil and water microbiomes. Additionally, the development of breed-specific withdrawal interval recommendations, as suggested by Chen et al., would enhance both therapeutic efficacy and food safety [4]. Strategies to mitigate resistome expansion, such as synbiotic co-administration, merit further investigation in field settings [7].

Conclusion

Enrofloxacin remains a valuable antimicrobial agent in avian medicine due to its favorable pharmacokinetic profile, broad spectrum of activity, and established efficacy against key bacterial pathogens. However, its use is increasingly constrained by regulatory restrictions, concerns over antimicrobial resistance, and the persistence of residues in feathers and edible tissues [4, 5, 6, 7, 1]. PK/PD-optimized dosing, adherence to withdrawal periods, and integration of stewardship principles are essential to preserve the clinical utility of enrofloxacin while minimizing risks to public health and the environment. A comprehensive understanding of breed-specific pharmacokinetics, drug interactions, and resistome dynamics will inform future guidelines for [avian enrofloxacin] use [4, 10, 7].

References

[1] Soh HY, Tan PXY, Ng TTM et al. A Critical Review of the Pharmacokinetics, Pharmacodynamics, and Safety Data of Antibiotics in Avian Species. Antibiotics (Basel). 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35740148/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[2] Felix LA, Egito BM, David DD et al. Pharmacokinetics, pharmacodynamic efficacy prediction indices, and Monte Carlo simulations of enrofloxacin for the treatment of colibacillosis in broiler chickens. Open Vet J. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41200291/

[3] Fuchs K, Rinder M, Dietrich R et al. Penetration of Enrofloxacin in Aqueous Humour of Avian Eyes. Vet Sci. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36669006/

[4] Chen D, Wang C, Liu Y et al. A comprehensive study on enrofloxacin residue depletion in five chicken breeds. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42056824/

[5] Ringenier M, Cherlet M, Dewulf J et al. Continued presence of enrofloxacin residues in feathers of broiler parent stock based on quantitative UHPLC-MS/MS detection. Poult Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40187010/

[6] Ringenier M, Cherlet M, Dewulf J et al. Residue depletion of enrofloxacin and flumequine in feathers of broilers based on quantitative UHPLC-MS/MS detection. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38935119/

[7] Temmerman R, Ghanbari M, Antonissen G et al. Dose-dependent impact of enrofloxacin on broiler chicken gut resistome is mitigated by synbiotic application. Front Microbiol. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35992659/

[8] Wei Y, Li Y, Zhao H et al. Pharmacokinetic/pharmacodynamic relationships of enrofloxacin against Klebsiella pneumoniae in an in vivo infection model in young chicks. Poult Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38833743/

[9] Petkova T, Milanova A, Poźniak B. The effects of cyclosporine A or activated charcoal co-administration on the pharmacokinetics of enrofloxacin in chickens. Poult Sci. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/36343435/

[10] Deng H, Kong Q, Gao Y et al. Dual mechanisms of morin in bioavailability potentiation and hepatoprotection: Enhancing enrofloxacin safety in poultry through ABC transporter inhibition and antioxidant pathway activation. Vet J. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41887316/

[11] Abbasnia M, Mosleh N, Dadras H et al. Effect of enrofloxacin on clinical parameters and mucociliary system of broilers challenged with H9N2 avian influenza/infectious bronchitis viruses. Vet Med Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38419286/